{"id":17002,"date":"2014-02-28T11:04:15","date_gmt":"2014-02-28T16:04:15","guid":{"rendered":"http:\/\/sciencebusiness.technewslit.com\/?p=17002"},"modified":"2014-02-28T11:04:15","modified_gmt":"2014-02-28T16:04:15","slug":"life-sciences-investment-company-closes-new-fund","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=17002","title":{"rendered":"Life Sciences Investment Company Closes New Fund"},"content":{"rendered":"<figure id=\"attachment_5768\" aria-describedby=\"caption-attachment-5768\" style=\"width: 300px\" class=\"wp-caption alignleft\"><a href=\"http:\/\/www.flickr.com\/photos\/m4dgroup\/6001102681\/in\/photostream\/\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-5768\" alt=\"Currency dice (MD4 Group\/Flickr)\" src=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2011\/08\/CurrencyDice_M4DGROUP_Flickr.jpg\" width=\"300\" height=\"200\" srcset=\"https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2011\/08\/CurrencyDice_M4DGROUP_Flickr.jpg 300w, https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2011\/08\/CurrencyDice_M4DGROUP_Flickr-150x100.jpg 150w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><figcaption id=\"caption-attachment-5768\" class=\"wp-caption-text\">(M4D Group\/Flickr)<\/figcaption><\/figure>\n<p>28 February 2014. <a href=\"http:\/\/www.abingworth.com\/_news\/abingworth-raises-225m-final.pdf\">Abingworth LLP<\/a>, an investment company based in London, closed its 10th fund designed for financing life sciences and health care enterprises. The company says its Abingworth Bioventures VI\u00a0fund raised \u00a3225 million ($375 million), exceeding its target of \u00a3200 million.<\/p>\n<p>Abingworth expects its Bioventures VI\u00a0fund to invest in life sciences companies in Europe and the U.S., making 15 to 20\u00a0transactions ranging in size from \u00a35 to \u00a320 million ($8 to $33 million). The company says the fund plans to make early and late stage venture and growth-capital deals in privately owned, as well as selected public companies, known as Venture Investments in Public Equities or <a href=\"http:\/\/blogs.wsj.com\/venturecapital\/2009\/02\/19\/weve-heard-of-pipe-deals-but-vipes\/\">Vipes<\/a>.<\/p>\n<p>The Bioventures VI already closed four deals, two of which are in the U.S.:<\/p>\n<p>&#8211; <a href=\"http:\/\/www.avedro.com\/\">Avedro Inc.<\/a> in Waltham, Massachusetts, developing corneal collagen cross-linking therapies to treat eye disorders, such as keratoconus causing visual distortions and post-Lasik ectasia or thinning of the cornea.<\/p>\n<p>&#8211; <a href=\"http:\/\/avillionllp.com\/\">Avillion LLP<\/a> in London, that funds and manages late-stage clinical trials for regulatory drug approvals<\/p>\n<p>&#8211; <a href=\"http:\/\/effector.com\/\">eFFECTOR Therapeutics<\/a> in San Diego, developing small-molecule drugs as cancer treatments<\/p>\n<p>&#8211; <a href=\"http:\/\/www.gensight-biologics.com\/\">GenSight Biologics<\/a> in Paris, a developer of gene therapies for degenerative retinal disorders<\/p>\n<p>In addition to pharmaceutical and biotechnology companies, Abingworth <a href=\"http:\/\/www.abingworth.com\/criteria.jsp\">also invests<\/a> in companies designing medical devices, instrumentation, and health services. Abingworth says it brings to its portfolio companies legal, investment banking, operating and recruiting capabilities, and can call on a network of scientific and industry consultants.<\/p>\n<p>Read more:<\/p>\n<ul>\n<li>\n<div><a href=\"http:\/\/sciencebusiness.technewslit.com\/?p=16847\">Science-Based Enterprises: Great Ideas Beat Venture Capital<\/a><\/div>\n<\/li>\n<li>\n<div><a href=\"http:\/\/sciencebusiness.technewslit.com\/?p=16818\">Start-Up Developing Gene Therapies Lands $45M in Early Funds<\/a><\/div>\n<\/li>\n<li>\n<div><a href=\"http:\/\/sciencebusiness.technewslit.com\/?p=16200\">Genome Editing Start-Up Secures $43M in First Round Funds<\/a><\/div>\n<\/li>\n<li>\n<div><a href=\"http:\/\/sciencebusiness.technewslit.com\/?p=16119\">Inflammation Drug Biotech Lands $32.4M in Venture Funding<\/a><\/div>\n<\/li>\n<li>\n<div><a href=\"http:\/\/sciencebusiness.technewslit.com\/?p=15514\">Investment Fund to Finance Global Health Technologies<\/a><\/div>\n<\/li>\n<\/ul>\n<p style=\"text-align: center;\">*\u00a0\u00a0\u00a0\u00a0 *\u00a0\u00a0\u00a0\u00a0 *<\/p>\n","protected":false},"excerpt":{"rendered":"<p>28 February 2014. Abingworth LLP, an investment company based in London, closed its 10th fund designed for financing life sciences and health care enterprises. The company says its Abingworth Bioventures VI\u00a0fund raised \u00a3225 million ($375 million), exceeding its target of \u00a3200 million. Abingworth expects its Bioventures VI\u00a0fund to invest in life sciences companies in Europe [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[31,21,74,23,24,64,90,19],"class_list":["post-17002","post","type-post","status-publish","format-standard","hentry","category-finance","tag-biomedical","tag-biotech","tag-entrepreneurs","tag-equity","tag-investment","tag-life-sciences","tag-u-k","tag-venture-capital"],"_links":{"self":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/17002","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=17002"}],"version-history":[{"count":4,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/17002\/revisions"}],"predecessor-version":[{"id":17006,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/17002\/revisions\/17006"}],"wp:attachment":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=17002"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=17002"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=17002"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}